Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

OBJECTIVES: COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero, Armando, Filgueira, Lázaro M, Betancourt, Julio, Sánchez, Naivy, Hidalgo, Carlos, Ramírez, Alberto, Martinez, Alejandro, Despaigne, Rolando E, Escalona, Alberto, Diaz, Henrry, Meriño, Elio, Ortega, Lilia M, Castillo, Ulises, Ramos, Mayra, Saavedra, Danay, García, Yanelda, Lorenzo, Geydi, Cepeda, Meylán, Arencibia, Maylén, Cabrera, Leticia, Domecq, Milagros, Estévez, Daymys, Valenzuela, Carmen, Lorenzo, Patricia, Sánchez, Lizet, Mazorra, Zaima, León, Kalet, Crombet, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688906/
https://www.ncbi.nlm.nih.gov/pubmed/33304584
http://dx.doi.org/10.1002/cti2.1218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688906/
https://www.ncbi.nlm.nih.gov/pubmed/33304584
http://dx.doi.org/10.1002/cti2.1218

Ejemplares similares